Zeta WT-1 Antibody. Zeta’s recombinant mouse antibody recognizes WT-1, a suppressor gene located on chromosome 11p13. Wilm’s Tumor Protein (WT-1) has been identified in proliferative mesothelial cells, malignant mesothelioma, ovarian cystadenocarcinoma, gonadoblastoma, nephroblastoma and desmoplastic small round cell tumor. Lung adenocarcinomas rarely stain positive with the WT-1 antibody.
WT-1 is a transcription factor essential for normal development of the urogenital system. WT-1 has both tumor suppressing and tumorigenic role in several neoplasias, including breast, acute myeloid leukemia and mesothelioma. WT-1 affects genes of the Wnt and β-catenin pathway and p53 tumor suppressor pathway. WT-1 is expressed in a broad spectrum of tumors, including malignant mesothelioma, ovarian serous epithelial tumors and sex cord stromal tumors, astrocytoma, glioblastoma, benign and malignant vascular tumors and desmoplastic malignant melanoma. WT-1 expression is linked to poor prognosis of several tumors, including acute myeloid leukemia, pancreatic and colorectal cancers and astrocytoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.